Ionis Pharmaceuticals (IONS) Revenue (2009 - 2026)

Ionis Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $267.9 million for Q2 2026.

• In Q2 2026, Revenue fell 40.73% year-over-year to $267.9 million; the TTM figure through Jun 2026 stood at $678.0 million (down 28.18% YoY), while the FY2025 annual figure was $943.7 million, up 33.83% from the prior year.
• Revenue for Q2 2026 stood at $267.9 million, up from $50.0 million in the prior quarter.
• The five-year high for Revenue was $452.0 million in Q2 2025, with the low at $50.0 million in Q1 2026.
• The 5-year median for Revenue is $154.3 million (2022), against an average of $185.7 million.
• The sharpest annual moves came in 2022 and 2023: Revenue tumbled 65.48% in 2022, then surged 113.64% in 2023.
• Ionis Pharmaceuticals' Revenue stood at $151.9 million in 2022, then surged by 113.64% to $324.5 million in 2023, then sank by 30.18% to $226.6 million in 2024, then dropped by 10.26% to $203.3 million in 2025, then surged by 31.78% to $267.9 million in 2026.
• Business Quant data shows IONS's Revenue at $267.9 million in Q2 2026, $50.0 million in Q1 2026, and $203.3 million in Q4 2025.